Stock Analysis on Net
Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Zoetis Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income attributable to Zoetis Inc. 2,344 2,114 2,037 1,638 1,500
Net loss attributable to noncontrolling interests (4) (3) (3) (2) —
Net noncash charges 525 500 522 575 446
Other changes in assets and liabilities, net of acquisitions and divestitures (512) (699) (343) (85) (151)
Net cash provided by operating activities 2,353 1,912 2,213 2,126 1,795
Cash paid during the period for interest, net of capitalized interest, net of tax1 235 192 207 211 206
Capitalized interest expense, net of tax2 22 17 16 14 11
Capital expenditures (732) (586) (477) (453) (460)
Free cash flow to the firm (FCFF) 1,878 1,535 1,959 1,898 1,552

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


An analysis of the financial performance from 2019 to 2023 reveals a generally positive trajectory in cash generation, characterized by a significant dip in 2022 followed by a strong recovery in 2023.

Net Cash Provided by Operating Activities
Operating cash flow demonstrated an overall upward trend, growing from 1,795 million US$ in 2019 to a peak of 2,353 million US$ in 2023. Growth was consistent through 2021, reaching 2,213 million US$, before experiencing a contraction of approximately 13.6% in 2022 to 1,912 million US$. The subsequent rebound in 2023 represents the highest operational cash generation within the observed five-year period.
Free Cash Flow to the Firm (FCFF)
FCFF followed a pattern closely aligned with operating cash flows, increasing from 1,552 million US$ in 2019 to 1,959 million US$ by 2021. A more pronounced decline occurred in 2022, where FCFF dropped to 1,535 million US$, a decrease of approximately 21.6% from the previous year. By 2023, FCFF recovered to 1,878 million US$, although this remains below the 2021 peak.
Cash Conversion and Capital Intensity
The variance between operating cash flow and FCFF indicates a trend of increasing capital expenditure or investment requirements. In 2019, the gap was 243 million US$, whereas by 2023, this difference expanded to 475 million US$. The conversion rate of operating cash to FCFF declined from a high of approximately 89% in 2020 to 80% in 2023, suggesting a shift toward higher capital intensity to support operations or growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Interest Paid, Net of Tax

Zoetis Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR1 20.30% 20.50% 18.20% 18.00% 16.70%
Interest Paid, Net of Tax
Cash paid during the period for interest, net of capitalized interest, before tax 295 242 253 257 247
Less: Cash paid during the period for interest, net of capitalized interest, tax2 60 50 46 46 41
Cash paid during the period for interest, net of capitalized interest, net of tax 235 192 207 211 206
Interest Costs Capitalized, Net of Tax
Capitalized interest expense, before tax 27 21 20 17 13
Less: Capitalized interest expense, tax3 5 4 4 3 2
Capitalized interest expense, net of tax 22 17 16 14 11

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 2023 Calculation
Cash paid during the period for interest, net of capitalized interest, tax = Cash paid during the period for interest, net of capitalized interest × EITR
= 295 × 20.30% = 60

3 2023 Calculation
Capitalized interest expense, tax = Capitalized interest expense × EITR
= 27 × 20.30% = 5


The financial data reveals a general upward trajectory in both the effective tax burden and the costs associated with interest expenditures over the five-year period from 2019 to 2023. While cash interest payments exhibited some volatility, the capitalized interest expenses showed a consistent linear increase.

Effective Income Tax Rate Trends
The effective income tax rate experienced a steady increase from 16.70% in 2019 to a peak of 20.50% in 2022, before settling slightly at 20.30% in 2023. This represents an overall increase of 360 basis points over the analyzed period, indicating a higher proportional tax obligation on taxable income.
Net Cash Interest Outflows
Cash paid for interest, net of capitalized interest and tax, remained relatively stable between 2019 and 2021, fluctuating between 206 million and 211 million US dollars. A contraction occurred in 2022, with payments dropping to 192 million US dollars, followed by a significant increase to 235 million US dollars in 2023. This final increase marks the highest cash interest outflow in the recorded period.
Capitalized Interest Growth
Capitalized interest expense, net of tax, demonstrated a consistent year-over-year increase throughout the entire period. Starting at 11 million US dollars in 2019, the figure grew annually to reach 22 million US dollars by 2023. This 100% increase suggests an expansion in the financing of long-term assets or infrastructure projects that qualify for interest capitalization.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Enterprise Value to FCFF Ratio, Current

Zoetis Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 80,835
Free cash flow to the firm (FCFF) 1,878
Valuation Ratio
EV/FCFF 43.05
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 26.68
Amgen Inc. 24.87
Bristol-Myers Squibb Co. 11.04
Danaher Corp. 29.47
Eli Lilly & Co. 117.21
Gilead Sciences Inc. 18.99
Johnson & Johnson 30.24
Merck & Co. Inc. 28.98
Pfizer Inc. 18.47
Regeneron Pharmaceuticals Inc. 18.36
Thermo Fisher Scientific Inc. 34.67
Vertex Pharmaceuticals Inc. 37.90
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 35.64
EV/FCFF, Industry
Health Care 30.72

Based on: 10-K (reporting date: 2023-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Zoetis Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 88,543 83,977 96,445 82,629 73,350
Free cash flow to the firm (FCFF)2 1,878 1,535 1,959 1,898 1,552
Valuation Ratio
EV/FCFF3 47.16 54.71 49.22 43.54 47.27
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 14.89 12.15 13.18 — —
Amgen Inc. 22.22 16.01 15.82 — —
Bristol-Myers Squibb Co. 9.14 13.87 10.52 — —
Danaher Corp. 36.34 25.74 28.25 — —
Eli Lilly & Co. 655.43 59.17 38.39 — —
Gilead Sciences Inc. 13.41 13.58 8.42 — —
Johnson & Johnson 19.30 23.80 21.25 — —
Merck & Co. Inc. 37.84 19.09 23.27 — —
Pfizer Inc. 32.24 9.15 8.40 — —
Regeneron Pharmaceuticals Inc. 25.33 23.31 9.81 — —
Thermo Fisher Scientific Inc. 28.85 31.61 33.14 — —
Vertex Pharmaceuticals Inc. 29.45 16.68 22.47 — —
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 27.29 18.08 16.12 — —
EV/FCFF, Industry
Health Care 25.98 18.66 17.80 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 See details »

3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 88,543 ÷ 1,878 = 47.16

4 Click competitor name to see calculations.


The financial performance from 2019 to 2023 is characterized by fluctuations in both enterprise value and the generation of free cash flow to the firm, resulting in a volatile valuation multiple. Enterprise value peaked in 2021 at 96,445 million US$ before experiencing a correction in 2022 and a moderate recovery to 88,543 million US$ by the end of 2023.

Free Cash Flow to the Firm (FCFF) Trends
FCFF exhibited a general upward trajectory from 2019 to 2021, rising from 1,552 million US$ to 1,959 million US$. A notable contraction occurred in 2022, where FCFF dropped to 1,535 million US$, representing the lowest level in the analyzed period. However, a recovery was observed in 2023, with FCFF returning to 1,878 million US$.
EV/FCFF Ratio Analysis
The EV/FCFF ratio remained elevated throughout the period, fluctuating between 43.54 and 54.71. The ratio reached its peak in 2022 at 54.71, which coincided with the period of lowest FCFF and a simultaneous decline in enterprise value. This indicates that the decline in cash flow generation outpaced the compression of the enterprise value during that fiscal year.
Valuation Convergence
By December 31, 2023, the EV/FCFF ratio normalized to 47.16, nearly identical to the 47.27 ratio recorded in 2019. This convergence suggests that despite the intermediate volatility in both cash flows and market valuation, the relationship between the enterprise value and the firm's ability to generate free cash flow has returned to its baseline level over the five-year cycle.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?